PHARMACOECONOMIC ISSUES OF ADALIMUMAB THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS

Background. Juvenile idiopathic arthritis (JIA) is the most common type of arthritis in children and is associated with reduced quality of life and increased health care costs. Objective. To evaluate the cost effectiveness of the tumour necrosis factor inhibitor adalimumab (ADA) vs. non-biologic the...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: K. Simpson, N. Marlow, J. Shaw, А. V. Rudakova
Materialtyp: Artigo
Språk:Inglês
Publicerad: Paediatrician Publishers, LLC 2012-08-01
Serie:Pediatričeskaâ Farmakologiâ
Ämnen:
juvenile idiopathic arthritis
adalimumab
cost-effectiveness analysis
Länkar:https://www.pedpharma.ru/jour/article/view/302
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk